Luly Jay R. → ENANTA PHARMACEUTICALS INC ENTA

Stake: 7.70% Shares: 1,703,616 CUSIP: 29251M106 Class: Common Stock, par value $0.01 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 28/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: -10.8%

Passive Schedule 13G filer baseline
High conviction ownership stake (7.7%)
Held by 1 tracked 13F institutional manager
8 NPORT-P mutual funds holding CUSIP
Elevated short days-to-cover (8.6 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 8.57

2,265,069 shares short · -11.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $6.92M

Point72 Asset Mgmt

Post-Filing Returns · since 2025-02-12 on ENTA

+1 day

+28.0%

+5 days

+27.8%

+30 days

+13.5%

+60 days

-15.9%

+90 days

-10.8%

+180 days

+10.8%

Anchor price 5.86 on closest trading day on/after 2025-02-12. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on ENANTA PHARMACEUTICALS INC

Filed	Form	Filer	Stake	Shares
2026-10-27	SCHEDULE 13G	BlackRock Portfolio Management LLC	—	—	view →
2020-03-04	SC	Luly Jay R.	—	—	view →

Other Filings by Luly Jay R.

Filed	Form	Issuer	Stake	Shares
2020-03-04	SC	ENANTA PHARMACEUTICALS INC ENTA	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →